Riskpilot← Back to searchSign inGet full accessHUBRO THERAPEUTICS AS
ASBankruptOrg 921833016Ullernchausséen 64, 0379 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20189 employees
Revenue 2022
NOK 0
EBITDA margin
—
-314% vs 2021
Equity ratio
43.6%
Financial strength
Net profit 2022
NOK -31,6M
-319% vs 2021
| Revenue | NOK 0 | — |
| EBITDA | NOK -31,7M | -314% |
| Net profit | NOK -31,6M | -319% |
| Total assets | NOK 83,6M | +17% |
| Equity | NOK 36,5M | -46% |
| Employees | 9 | — |
Legal name
HUBRO THERAPEUTICS AS
Org number
921833016
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
5. desember 2018
Share capital
NOK 413 587
Employees
9 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Daglig leder eller styrets leder hver for seg.
Company purpose
Utvikling og salg av biomedisinske produkter og tjenester. Formålet kan fremmes ved deltakelse i eller samarbeid med andre foretak i inn- og utland.
Address
Ullernchausséen 64, 0379 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenue | 750 | 0 | 54 | 0 |
| Staff expenses | −1 364 | −2 904 | −1 649 | −7 016 |
| EBITDA | −2 143 | −7 554 | −7 651 | −31 701 |
| Depreciation & amort. | −0 | −0 | −0 | −11 |
| EBIT | −2 143 | −7 554 | −7 651 | −31 713 |
| Net financials | 13 | 66 | 115 | 161 |
| Profit before tax | −2 130 | −7 488 | −7 537 | −31 552 |
| Tax | −578 | 578 | −0 | −0 |
| Net profit | −1 552 | −8 066 | −7 537 | −31 552 |
| Item | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Total assets | 5 991 | 15 023 | 71 600 | 83 592 |
| Equity | 5 622 | 14 056 | 68 020 | 36 468 |
| Long-term debt | 0 | 0 | 0 | 35 425 |
| Short-term debt | 369 | 967 | 3 580 | 11 699 |
| Total debt | 369 | 967 | 3 580 | 47 124 |
EBITDA margin
-3170143700.0%
This company
15.8%
Market median
-20064200733% vs market
20192022
Equity ratio
43.6%
This company
38.2%
Market median
+14% vs market
20192022
Return on equity
-86.5%
This company
18.4%
Market median
-570% vs market
20192022
Net profit margin
-3155168100.0%
This company
8.1%
Market median
-38952692693% vs market
20192022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192022
Debt / equity
1.29×
This company
0.62×
Market median
-108% vs market
20192022
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2018-11-20 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ØK Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (1) | ||
JA Chief Executive Officer | Chief Executive Officer | 2018 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Former (2) | ||
| Board of Directors | 2021 – 2023 | |
| Chairman | 2021 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 21.98% | 21.98% | 2023 | |
Ubs Switzerland Ag | Company | 21.3% | 21.3% | 2023 |
| Individual | 16.09% | 16.09% | 2022 | |
| Company | 10.02% | 10.02% | 2023 | |
| Company | 8.14% | 8.14% | 2023 | |
| Company | 7.36% | 7.36% | 2023 | |
| Company | 5.93% | 5.93% | 2023 | |
| Company | 4.51% | 4.51% | 2023 | |
| Company | 3.47% | 3.47% | 2023 | |
| Company | 3.26% | 3.26% | 2023 | |
Integrated Innovations Consulting | Company | 2.42% | 2.42% | 2023 |
| Company | 1.29% | 1.29% | 2023 | |
| Company | 1.25% | 1.25% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of HUBRO THERAPEUTICS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jon Amund Eriksen | Chief Executive Officer | 0 companies |
| Øyvind Kongstun Arnesen | Chief Executive Officer | 0 companies |
| Birgitte Gangmark Villmo | Board of Directors | 0 companies |
| Kjeld-Håkon Langeland Nilsen | Board of Directors | 0 companies |
| Tom Arne Thorsen | Board of Directors | 0 companies |
| Aitana Peire Morais | Board of Directors | 0 companies |
| Jonas Einarsson | Chairman | 0 companies |